Understanding the Potential Headwinds for Viatris Stock.

This afternoon we watched Viatris drop -3.9% to a price of $8.94 per share. The large-cap Medicinal Chemicals company is now trading -39.55% below its average target price of $14.78. Analysts have set target prices ranging from $10.0 to $35.0 per share for Viatris, and have given the stock an average rating of hold.

The stock has an average amount of shares sold short at 3.4%, and a short ratio of 4.02. The company's insiders own 0.32% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 78.2% of Viatris's shares being owned by this investor type.

Institutions Invested in Viatris

Date Reported Holder Percentage Shares Value
2023-06-30 Vanguard Group Inc 12% 144,495,498 $1,291,067,335
2023-06-30 Blackrock Inc. 7% 88,920,820 $794,507,564
2023-06-30 Davis Selected Advisers, LP 5% 62,948,155 $562,441,791
2023-06-30 State Street Corporation 5% 61,286,707 $547,596,752
2023-06-30 Price (T.Rowe) Associates Inc 4% 48,499,366 $433,341,855
2023-06-30 Geode Capital Management, LLC 2% 26,600,284 $237,673,548
2023-06-30 Camber Capital Management LP 2% 22,500,000 $201,037,509
2023-06-30 Invesco Ltd. 2% 22,300,746 $199,257,174
2023-06-30 Deerfield Management Company, L.P. (Series C) 1% 17,703,484 $158,180,636
2023-06-30 Pacer Advisors, Inc. 1% 15,661,796 $139,938,153

Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Viatris.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.